17 alpha-hydroxyprogesterone caproate has been researched along with amoxapine in 2 studies
Studies (17 alpha-hydroxyprogesterone caproate) | Trials (17 alpha-hydroxyprogesterone caproate) | Recent Studies (post-2010) (17 alpha-hydroxyprogesterone caproate) | Studies (amoxapine) | Trials (amoxapine) | Recent Studies (post-2010) (amoxapine) |
---|---|---|---|---|---|
517 | 88 | 251 | 392 | 50 | 52 |
Protein | Taxonomy | 17 alpha-hydroxyprogesterone caproate (IC50) | amoxapine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.0038 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.013 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.623 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.737 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.856 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 1.314 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 10 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.192 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.2 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.558 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.174 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 1.781 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.392 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.013 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.306 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0038 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.034 | |
Histamine H1 receptor | Homo sapiens (human) | 0.099 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.134 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.01 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.076 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
1 review(s) available for 17 alpha-hydroxyprogesterone caproate and amoxapine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for 17 alpha-hydroxyprogesterone caproate and amoxapine
Article | Year |
---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |